GLOW BLEND Components in Oral and Dental Research: Tooth Development, Periodontal Ligament, Oral Wounds and Evidence Gaps

RESEARCH · GLOW BLEND · ORAL, DENTAL AND PERIODONTAL MODELS

GLOW BLEND Components in Oral and Dental Research: Tooth Development, Periodontal Ligament, Oral Wounds and Evidence Gaps

PurixLab’s GLOW BLEND 70mg is a research vial combining BPC-157, TB-500 and GHK-Cu. Our earlier articles cover the blend’s components, dermal wound models, cornea and ocular surface models and angiogenesis. This article turns to a part of the body none of those covered: the mouth. Teeth, gums, the periodontal ligament and the oral mucosa have their own research literature for the blend’s components, and it is uneven. Most of it concerns thymosin beta-4, a little concerns BPC-157, and for GHK-Cu we found essentially none. These are findings from published research on the individual molecules; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Why the mouth is a distinct model system

Oral tissues heal under conditions the skin does not face: saliva, a dense bacterial biofilm, chewing forces and a ligament that anchors tooth to bone. Dedicated models include tooth-germ cultures from embryonic mouse jaws, odontoblast and dental epithelial cell lines, human periodontal ligament and gingival fibroblast cultures, tooth-extraction sockets and palatal wounds in rats, and ligature-induced periodontitis, where a thread tied around a molar drives inflammation and bone loss.

Thymosin beta-4 is already in the mouth

Unlike most research peptides, thymosin beta-4 is a normal component of oral fluids. An enzyme immunoassay study detected it in saliva and tears from three age groups, at concentrations of 0.2-3.6 micrograms per millilitre in saliva, with levels that appeared to peak at ages 25-35 [1]. A mass-spectrometry study then looked at where it comes from. Thymosin beta-4 was almost always present in whole saliva but undetectable in parotid saliva, and its mean concentration in gingival crevicular fluid, the fluid that seeps from the gum margin, was 200 times higher than in whole saliva. About 5% of the crevicular thymosin beta-4 was present as its sulfoxide, an oxidised form [2]. The authors concluded that the gingival sulcus is a main, though not the only, source of oral thymosin beta-4.

Tooth development: expression and knockdown studies

A Japanese group mapped thymosin beta-4 mRNA in the developing mouse lower first molar. It appeared in the presumptive dental epithelium at embryonic day 10.5 and then moved through the enamel organ and inner enamel epithelium as the tooth germ developed [3]. Blocking it with antisense oligonucleotides in cultured embryonic jaws inhibited tooth-germ growth at an early stage but not at a later one. Knockdown also lowered expression of Runx2 and nucleolin, genes the same group had linked to tooth development [4]. In a dental epithelial cell line, silencing thymosin beta-4 reduced signalling through Smad1/5 and Akt, which the authors connected to Runx2 expression and calcification [5]. The group also transfected the gene into HaCaT skin keratinocytes, which are not dental cells. Selected clones expressed enamel-related genes such as amelogenin and formed calcified nodules [6].

In odontoblasts, the cells that form dentin, a Korean group found thymosin beta-4 throughout the cytoplasm after birth, and silencing it in the MDPC-23 cell line reduced mineralisation-related genes including dentin sialophosphoprotein [7]. Transgenic mice that over-expressed thymosin beta-4 from a skin-specific promoter had accelerated hair growth but also abnormally shaped white teeth and dull incisors [8].

Periodontal ligament, dental pulp and a retraction

Two cell-culture papers looked at human periodontal ligament cells. In the first, thymosin beta-4 expression rose as the cells differentiated; silencing it reduced markers of bone- and cementum-like differentiation, while a thymosin beta-4 peptide increased them through several signalling pathways including NFATc1 [9]. In the second, oxidative stress with hydrogen peroxide lowered thymosin beta-4 in these cells. The peptide reduced inflammatory mediators and, in mouse bone-marrow macrophages, inhibited osteoclast differentiation [10].

A closely related 2013 paper from an overlapping group of authors reported that thymosin beta-4 promoted odontoblast-like differentiation of human dental pulp cells [11]. PLOS One retracted it in 2025. The editors cited apparent vertical discontinuities in several figure panels and blot panels that appeared similar across different figures, and noted that the authors did not respond to requests for underlying data [12]. The retraction does not by itself invalidate the periodontal ligament papers, which are separate publications, but it does mean the pulp findings should not be relied on, and the ligament findings have not, to our knowledge, been independently replicated.

Oral wounds and extraction sockets in rats

The in vivo work is small. After extraction of the rat mandibular first molar, a synthetic partial peptide of thymosin beta-4 given systemically suppressed apoptosis and inflammation and accelerated socket healing, including new bone formation [13]. The same group reported more new bone in critical-sized skull defects in rats, although bone-related gene expression at day 10 did not differ significantly between groups [14]. Both studies used a synthetic partial peptide of thymosin beta-4 rather than the full-length protein, and neither abstract describes the material as TB-500. In a palatal mucosa model, thymosin beta-4 stimulated migration of cultured rat palatal cells at 100 and 1,000 ng/mL without changing viability, raised MMP2 and VEGF expression, and significantly enhanced closure of 3 mm palatal wounds [15].

In cultured human gingival fibroblasts, thymosin beta-4 suppressed IL-8 secretion after stimulation with TNF-alpha and protected the cells against the cytotoxic effects of chlorhexidine and carbamide peroxide. It did not protect against lipopolysaccharide from Porphyromonas gingivalis or Escherichia coli [16], a notable gap given that bacterial products drive periodontal disease.

BPC-157: one periodontitis study

For BPC-157, the most directly relevant paper is a 2009 rat study of ligature-induced periodontitis. The peptide had no effect on blood flow in healthy gingiva. Given over 12 days, it significantly reduced plasma extravasation, histological inflammation and alveolar bone loss measured by micro-CT [17]. The broader BPC-157 literature from the Zagreb group includes a strong-alcohol model in which alcohol was applied at the tongue and swallowed, and lesions were assessed from the tongue to the duodenum [18]. A pain study published in a dental anaesthesia journal used a hind-paw incision, not an oral one, and found only a short-lived anti-nociceptive effect [19]. A 2026 report of three uncontrolled clinical cases of inferior alveolar nerve injury managed with a multimodal regimen that included BPC-157 and thymosin beta-4 derivatives is explicitly hypothesis-generating; the authors state that spontaneous recovery and confounding cannot be excluded and causality cannot be established [20].

GHK-Cu: a gap

We searched PubMed for GHK or GHK-Cu combined with periodontal, gingival, dental pulp and oral terms and did not find primary studies of the copper peptide in oral tissue models. Its dermal, bone and wound literature is covered in our GHK-Cu articles, but extrapolating from skin fibroblasts to a biofilm-exposed gingival margin would be speculation.

Reading this literature critically

  • Mostly one molecule. Nearly all the oral data concern thymosin beta-4, and much of the developmental work comes from one research network [3,4,5,6].
  • Which sequence? The extraction and skull-defect studies used a partial peptide of thymosin beta-4 [13,14]. Results with full-length protein or one fragment cannot be transferred automatically to another sequence, including whatever is sold as TB-500.
  • A retraction in the evidence base. The dental pulp paper has been retracted for unresolved figure concerns [12].
  • A cancer signal in oral cells. Over-expression of thymosin beta-4 in oral squamous cell carcinoma lines increased proliferation, invasion and markers of epithelial-to-mesenchymal transition [21]. Over-expression is not the same as adding the peptide from outside, but it is a reason for caution in oral models.
  • Single BPC-157 study. The periodontitis result has not been replicated by another group in the abstracts we reviewed [17].
  • No combination data. No study we found tested BPC-157, thymosin beta-4 or TB-500 and GHK-Cu together in any oral model.

What remains open

It is not known how added peptides behave against the existing thymosin beta-4 background in crevicular fluid, or how saliva and oral proteases affect stability. A blend with a copper peptide adds questions about metal binding and oxidation. Controlled, independently replicated animal studies with defined sequences, and assays that include bacterial challenge, would be needed before the oral literature could be called more than preliminary.

GLOW BLEND 70mg at PurixLab

GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View GLOW BLEND 70mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Badamchian M, Damavandy AA, Damavandy H, et al. Identification and quantification of thymosin beta4 in human saliva and tears. Ann N Y Acad Sci. 2007;1112:458-65. PubMed 17600285 · doi:10.1196/annals.1415.046
  2. Inzitari R, Cabras T, Pisano E, et al. HPLC-ESI-MS analysis of oral human fluids reveals that gingival crevicular fluid is the main source of oral thymosins beta(4) and beta(10). J Sep Sci. 2009;32(1):57-63. PubMed 19035385 · doi:10.1002/jssc.200800496
  3. Akhter M, Kobayashi I, Kiyoshima T, et al. Possible functional involvement of thymosin beta 4 in developing tooth germ of mouse lower first molar. Histochem Cell Biol. 2005;124(3-4):207-13. PubMed 16133119 · doi:10.1007/s00418-005-0040-x
  4. Ookuma YF, Kiyoshima T, Kobayashi I, et al. Multiple functional involvement of thymosin beta-4 in tooth germ development. Histochem Cell Biol. 2013;139(2):355-70. PubMed 23052839 · doi:10.1007/s00418-012-1033-1
  5. Someya H, Fujiwara H, Nagata K, et al. Thymosin beta 4 is associated with RUNX2 expression through the Smad and Akt signaling pathways in mouse dental epithelial cells. Int J Mol Med. 2015;35(5):1169-78. PubMed 25739055 · PMC4380193 · doi:10.3892/ijmm.2015.2118
  6. Kiyoshima T, Fujiwara H, Nagata K, et al. Induction of dental epithelial cell differentiation marker gene expression in non-odontogenic human keratinocytes by transfection with thymosin beta 4. Stem Cell Res. 2014;12(1):309-22. PubMed 24342703 · doi:10.1016/j.scr.2013.11.006
  7. Choi BD, Yun SH, Jeong SJ, et al. Expression of thymosin β4 in odontoblasts during mouse tooth development. Int J Mol Med. 2012;29(5):841-7. PubMed 22344518 · doi:10.3892/ijmm.2012.913
  8. Cha HJ, Philp D, Lee SH, et al. Over-expression of thymosin beta 4 promotes abnormal tooth development and stimulation of hair growth. Int J Dev Biol. 2010;54(1):135-40. PubMed 20013654 · doi:10.1387/ijdb.082735hc
  9. Lee SI, Lee DW, Yun HM, et al. Expression of thymosin beta-4 in human periodontal ligament cells and mouse periodontal tissue and its role in osteoblastic/cementoblastic differentiation. Differentiation. 2015;90(1-3):16-26. PubMed 26361868 · doi:10.1016/j.diff.2015.08.003
  10. Lee SI, Yi JK, Bae WJ, et al. Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells. PLoS One. 2016;11(1):e0146708. PubMed 26789270 · PMC4720371 · doi:10.1371/journal.pone.0146708
  11. Lee SI, Kim DS, Lee HJ, et al. The role of thymosin beta 4 on odontogenic differentiation in human dental pulp cells. PLoS One. 2013;8(4):e61960. PubMed 23613983 · PMC3629154 · doi:10.1371/journal.pone.0061960
  12. PLOS One Editors. Retraction: The role of thymosin beta 4 on odontogenic differentiation in human dental pulp cells. PLoS One. 2025;20(3):e0320021. PubMed 40029897 · PMC11875337 · doi:10.1371/journal.pone.0320021
  13. Matsuo K, Akasaki Y, Adachi K, et al. Promoting effects of thymosin β4 on granulation tissue and new bone formation after tooth extraction in rats. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(1):17-26. PubMed 22732845 · doi:10.1016/j.tripleo.2011.05.025
  14. Adachi K, Matsuo K, Akasaki Y, et al. Effects of thymosin β4 on the bone formation of calvarial defects in rats. J Prosthodont Res. 2013;57(3):162-8. PubMed 23490448 · doi:10.1016/j.jpor.2013.01.008
  15. Zhu T, Park HC, Son KM, et al. Effects of thymosin β4 on wound healing of rat palatal mucosa. Int J Mol Med. 2014;34(3):816-21. PubMed 24993983 · doi:10.3892/ijmm.2014.1832
  16. Reti R, Kwon E, Qiu P, et al. Thymosin beta4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):424-30. PubMed 18821984 · doi:10.1111/j.1600-0722.2008.00569.x
  17. Keremi B, Lohinai Z, Komora P, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009;60 Suppl 7:115-22. PubMed 20388954
  18. Becejac T, Cesarec V, Drmic D, et al. An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system. J Physiol Pharmacol. 2018;69(3). PubMed 30279308 · doi:10.26402/jpp.2018.3.11
  19. Jung YH, Kim H, Kim H, et al. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. J Dent Anesth Pain Med. 2022;22(2):97-105. PubMed 35449779 · PMC8995671 · doi:10.17245/jdapm.2022.22.2.97
  20. Froum S, Estrin N, Pico G, et al. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026;7:1907109. PubMed 42876687 · PMC13661421 · doi:10.3389/froh.2026.1907109
  21. Hong KO, Lee JI, Hong SP, et al. Thymosin β4 induces proliferation, invasion, and epithelial-to-mesenchymal transition of oral squamous cell carcinoma. Amino Acids. 2016;48(1):117-27. PubMed 26276576 · doi:10.1007/s00726-015-2070-6

Leave a Comment

Your email address will not be published. Required fields are marked *